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The Impact of Circulating Cholesterol Crystals
on Vasomotor Function
Implications for No-Reflow Phenomenon
Nitesh Gadeela, MD,* Jack Rubinstein, MD,* Umesh Tamhane, MD,*
Ruiping Huang, PHD,* Dorothy R. Pathak, PHD,‡ Hazel-Ann Hosein, PHD,§
Michael Rich, BSC,§ Gaurav Dhar, MD,* George S. Abela, MD, MSC*†
East Lansing, Michigan; and Cincinnati, Ohio
Objectives The purpose of this study was to determine if cholesterol crystals can injure the endothelial
surface by their jagged edges altering vasoreactivity and contributing to no-reﬂow after intervention.
Background After plaque rupture, cholesterol crystals are released into the circulation and ﬂow
ownstream contacting the arterial wall.
ethods Both carotid arteries from 22 rabbits were placed in a dual perfusion chamber and chal-
enged with norepinephrine followed by acetylcholine and nitroprusside. Arterial diameters were
easured before and after exposure to cholesterol crystals or microspheres and compared with di-
meters of normal control arteries. Arteries were examined by light, confocal, atomic force and scan-
ing electron microscopy.
esults Pre-exposure mean arterial diameter was 2.33  0.27 mm. With baseline norepinephrine
there was vasoconstriction of 0.82  0.19 mm, 0.79  0.18 mm, and 0.83  0.16 mm in lumen di-
ameter in the crystal, microsphere, and control groups, respectively. After cholesterol crystals or mi-
crospheres, vasoconstriction was signiﬁcantly less for cholesterol crystals but not for microspheres
(0.71  0.28 mm and 0.81  0.15 mm; p  0.02 and p  0.68). After acetylcholine in the same ar-
tery, there was signiﬁcantly less dilation before versus after crystals (0.49  0.24 mm vs. 0.38  0.22
mm, p  0.04) but not with microspheres or in the control group. There was no signiﬁcant differ-
ence after nitroprusside in any group, suggesting endothelial injury. By scanning electron micros-
copy, cholesterol crystals were found embedded in the intima with endothelial cell tears whereas
the microsphere treatment and control groups had minimal or no injury (93% vs. 31% vs. 14%;
p  0.01). By atomic force microscopy, surface roughness was signiﬁcantly greater with cholesterol
crystals compared with microspheres or in control arteries (p  0.05).
Conclusions Cholesterol crystals damaged the endothelium and reduced vasodilator response, po-
tentially aggravating myocardial ischemia after interventions. (J Am Coll Cardiol Intv 2011;4:521–9)
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522Atherosclerotic plaque rupture is considered the seminal
event in most acute cardiovascular syndromes (1–3).
owever, the subsequent release of plaque material laden
ith cholesterol crystals traveling downstream may pro-
uce intimal injury that impairs vascular function that
orsens ischemia and contributes to no-reflow after
ntervention (4 –13). Recently, we have demonstrated
hat plaque rupture is associated with cholesterol crystals
xtensively perforating the intima and their release into
he arterial lumen (14,15). Once the plaque cap is torn,
he contents, composed mostly of cholesterol crystals, are
eleased into the arterial circulation and embolize distally,
onstituting a major component of the occlusive throm-
oatheroma. During interventions, this material can then
hower and lodge in the distal vascular bed (4 –9,16). The
acute coronary occlusion responsible for myocardial in-
farction is the result of thrombosis (17) variably associ-
ted with local (18) and distal coronary vasoconstriction
11). Moreover, vasospasm has been shown to be more
requently present in patients with acute coronary syn-
romes, as well as those who have interventional proce-
dures with no-reflow.
The vascular endothelium nor-
mally regulates vasodilation via ni-
tric oxide (19,20). Although nitric
oxide and acetylcholine (ACh) are
both able to dilate coronary arter-
ies, the latter depends on an intact
endothelium to subsequently re-
lease nitric oxide and in cases
where the endothelium is dam-
aged will result in unopposed
vasoconstriction. Thus, we hy-
pothesize that flow of jagged crystals downstream from
the site of plaque rupture especially during interventions
can injure the intimal surface thus decreasing the
endothelial-dependant vasoreactivity. This study was de-
signed to investigate this process using normal rabbit
carotid arteries exposed to cholesterol crystals in an ex
vivo circuit to evaluate the endothelial response with
pharmacological challenge.
Methods
Arterial recruitment. Both carotid arteries from 22 New
Zealand White rabbits were used to evaluate the vasoreac-
tive response to pharmacological challenge of the arteries
before and after exposure to jagged and sharp tip cholesterol
crystals (n 24) as compared with exposure to smooth edge
microspheres (n  11) and phosphate buffered saline (PBS)
in normal control arteries (n  5). In 4 additional arteries,
Abbreviations
and Acronyms
ACh  acetylcholine
NE  norepinephrine
PBS  phosphate buffered
aline
EM  scanning electron
icroscopy
N  nitroprussidetechnical problems precluded obtaining vasoreactivitydata (2 with microspheres and 2 control arteries) but
those were available for morphological analysis. Rabbits
were euthanized by a dose of buthanesol solution (1 ml
intravenously; Virbac AH, Inc., Fort Worth, Texas) in
the ear vein. Carotid arteries were then rapidly dissected
by a mid-neck incision, gently removed, and placed in
PBS. The adherent tissues were carefully removed under
a dissecting microscope and then mounted in a dual
perfusion chamber (21). The study was approved by
Michigan State University committee on animal use
following National Institutes of Health guidelines.
Pharmacological challenge. Warm PBS (37°C) was circu-
ated in each of the divided perfusion chambers and
hrough the 2 arterial segments (Fig. 1). After a 20-min
eriod of stabilization, the arteries were pre-constricted
ith norepinephrine (NE) (1  106 mol/l) and then
hallenged with ACh (1  105 mol/l) followed by
nitroprusside (SN) (1  105 mol/l) for 20 min each to
valuate for both endothelial and smooth muscle reactivity (see
imeline in Fig. 1).
Vasodilation of the arteries was measured from the
diameter of each artery at 5 different locations. These
measurements were captured every 10 s during the
experiment by a digital camera (Pulnix TMC-7, Pulnix
America, Inc., Sunnyvale, California) and digitized im-
ages analyzed by a customized software package that was
written to measure lumen dimensions using border rec-
ognition of the arterial wall. At the end of baseline
pharmacological challenge, either crystals or micro-
spheres were injected from the side port into each of the
arterial segments and circulated for 30 min while only
PBS was circulated in the control arteries.
Cholesterol crystals. Crystals were made as previously re-
orted (22). Briefly, the crystals were grown in a substrate
omposed of trimethyl silicate gel made by dissolving
rimethyl silicate in water at pH  5 and specific gravity of
.03 with 30 ml of methanol and then set for 72 h. One
ram of cholesterol powder (5-Cholesten-3-beta-Ol;
-beta-hydroxy-5-cholestene [C27H46O]: molecular
eight  386.7; 95% to 98% pure) (Sigma, St. Louis,
issouri) was added to 200 ml methanol and then added
o the gel to form crystals within 48 h. These were then
assed through filter paper and cholesterol crystals al-
owed to dry in air. The crystals ranged in length from
00 to 300 m. After being injected into the artery and
llowed to circulate for a period of 30 min, they were
ashed out of the system with PBS and the artery was
llowed to stabilize for 20 min before the post-exposure
harmacological challenge. These synthetic crystals are
lmost identical in size and shape to those seen in human
laques (14,15,23).
Microspheres. The polystyrene microspheres (Poly-
sciences, Inc., Warrington, Pennsylvania) used ranged
from 200 to 300 m to match the size of the crystals.
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523Microspheres were injected, circulated, and washed out
with PBS before pharmacological challenge in a manner similar to
the crystals.
Microscopy to detect intimal injury. SCANNING ELECTRON
ICROSCOPY. At the conclusion of the circuit run, the
arteries were perfusion-fixed with 4% glutaraldehyde for
30 min. After 24 h, 5-mm long segments of artery were
chosen randomly from the artery and cut longitudinally
to expose the intimal surface and vacuum dehydrated over
12 h. As previously reported, this method avoids ethanol
dehydration to prevent dissolving the cholesterol crystals
(14,23). Samples were dried in a vacuum chamber (Speed
Vac SC110, Savant Instruments, Inc., Farmingdale, New
York) evacuated by a pump (VP110, Franklin Electric,
Bluffton, Indiana). Arterial segments were then mounted
on stubs and gold coated in a sputter coater (EMSCOPE
SC500, Quorum Technologies, Sussex, United King-
dom). The arterial lumen was then examined for intimal
damage by cholesterol crystals and microspheres using a
JEOL scanning electron microscope (SEM) (Model JSM-
6300F, JEOL Ltd., Tokyo, Japan). Images were evaluated by a
Figure 1. Experimental Setup
(A) Dual perfusion chamber with computer and camera setup. (B) Timeline of
NE  norepinephrine; PBS  phosphate buffered saline; SN  nitroprusside.blinded examiner.INTIMAL INJURY SCORE. Injury was scored as 0 for no
injury; 1 for localized endothelial cell injury without
disruption; 2 for localized injury with disrupted endothe-
lial cells; and 3 for loss of endothelial cells.
CONFOCAL MICROSCOPY. Arterial segments were stained
for cholesterol crystals using fluorescent dye (cholesteryl
BODIPY-C12, Invitrogen, Eugene, Oregon) (14). To dem-
nstrate the relationship of cholesterol crystals to the inti-
al surface, the endothelium was counterstained with eosin.
amples were then transferred to a slide incubator chamber
lled with PBS and visualized. Unstained plaque samples
ere also examined to detect native tissue fluorescence.
luorescence images of plaque were acquired using a Zeiss
ascal laser scanning microscope (Carl Zeiss, Inc., Jena,
ermany). Fluorescence was collected sequentially using
he argon 488-nm laser line for excitation of BODIPY and
ollecting green fluorescence with a 505 to 530 nm bandpass
lter and using the HeNe 543-nm laser line for excitation of
osin and collecting red fluorescence with a 560-nm long
ass filter.
ATOMIC FORCE MICROSCOPY. The effect of perfusion on
rious pharmacological challenges and interventions. ACh  acetylcholine;the vaintimal surface roughness was also evaluated using atomic
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524force microscopy. One-centimeter long segments of per-
fused arteries were mounted on a steel stub and images were
collected on a Nanoscope IV instrument (Veeco, Santa
Barbara, California) equipped with a J scanner. Images were
collected in tapping mode, using commercially available
silicon cantilevers. All scans were collected at a rate of 0.5
Hz using a low pass filter, and scan lines were erased. Two
roughness parameters were collected, namely, Ra the arith-
metic average of the deviations from the center plane, and
RMS, the standard deviation of Z values within a given
rea. The measurements were collected in a blinded fashion
o the operator.
LIGHT MICROSCOPY. Light microscopy was performed in
the standard fashion. After fixation in 4% glutaraldehyde
and serial ethanol dehydration, tissues were embedded in
paraffin and cut at 5-m thick sections while stepping into
he whole block every 2 mm. Arterial sections were stained
ith hematoxylin and eosin or trichrome and examined for
resence of intimal injury under a light microscope (Leitz
aborlux12, Oberkochen, Germany).
Statistical analysis. Statistical analysis was performed using
AS (SAS Institute, Inc., Cary, North Carolina) and InStat 3
Graph Pad, San Diego, California). Data are reported as
ean  SD. The change in arterial diameter with NE,
ACh, and SN challenge was compared in the same artery
before and after cholesterol crystals, microspheres, or PBS
circulation using a paired t test. The roughness measure-
ments between untreated control and treated arteries
with crystals and microspheres were compared using a
1-way analysis of variance followed by Tukey multiple
comparisons test for individual comparisons between the
subgroups. A Fisher exact test was used for categorical vari-
ables. A 2-sided p value 0.05 was considered statistically
significant.
Results
Physiological response. A total of 40 carotid arteries were
tudied after exposure to PBS at 37°C followed by choles-
erol crystals (n  24), microspheres (n  11), or only PBS
n controls (n  5). The mean diameter of all the arteries at
aseline was 2.33 0.27 mm. After PBS, the baseline mean
asoconstrictor response to NE was 0.82  0.19 mm, 0.79 
.18 mm, and 0.83  0.16 mm in lumen diameter for
rystal-, microsphere-, and PBS-treated arteries, respec-
ively. After crystal or microsphere exposure, the diameter
eduction was 0.71  0.28 mm with crystals and 0.81 
.15 mm with microspheres (p  0.02 and p  0.68,
espectively). The baseline mean vasodilatory response to
Ch after NE pre-constriction was 0.49  0.24 mm as
ompared to 0.38  0.22 mm after crystals (p  0.04), and
no significant change was observed after microspheres or in
the PBS control groups (Fig. 2). Also, there was no
significant difference in vasodilatory response after SNexposure at baseline and after treatment with crystal, mi-
crosphere, and PBS. All arteries returned to their baseline
state after vasodilation.
Microscopy. SEM of the arterial intima was performed in
35 arterial segments (Table 1). This demonstrated various
degrees of intimal injury evidenced by tears and cholesterol
Figure 2. Lumen Diameters With Pharmacological Challenges
Change in mean lumen diameter comparing cholesterol crystal-, microsphere-, and
PBS-treated arteries challenged with NE, ACh, and SN. Abbreviations as in Figure 1.crystals embedded in the endothelium (Fig. 3). Circular
ep
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525imprints with a “roller like” effect were rarely detected in
microsphere-treated arteries, otherwise only minimal dis-
ruption of the intima was noted. With the exception of 1
Table 1. Degree of Intimal Injury by SEM
Type of Injury Cholesterol Crystals* Microspheres† Control Arteries
None 1 9 6
I 7 2 1
II 5 2 0
III 2 0 0
Total 15 13 7
p values adjusted for multiple comparisons by Bonferroni method. *p 0.01 for cholesterol
crystals versus microspheres and cholesterol crystals versus control arteries. †p NS for micro-
spheres versus controls.
SEM scanning electron microscopy.
Figure 3. SEM and Fluorescence Images After Treatment
Microscopic images (scanning electron microscopy [SEM]: A to I; confocal microscopy
K), and cholesterol crystals (C, F, I, and L). No intimal injury is present with control art
lesterol crystals. With confocal microscopy, a microsphere can be seen attached to the surfacsmall site, there was no intimal injury in PBS-perfused
control arteries. There were significantly more sites of
intimal injury observed with cholesterol crystals than with
microspheres and in control arteries (p  0.01), but no
difference was noted between microsphere and control
arteries. Intimal injury was focal and detected mainly at sites
with the presence of cholesterol crystals. These data com-
plement the physiological findings with respect to the
severity of injury. Also, no microspheres were detected by
SEM in any of the examined samples whereas cholesterol
crystals were detected in all treated samples (Table 2). How-
ver, microspheres were detected by confocal microscopy.
Confocal microscopy was performed in 11 arterial sam-
les (Table 2). Cholesterol crystals could be detected in 10
f 11 (90%), whereas microspheres were detected in only 7
) of arterial surface injury with control (A, D, G, and J), microspheres (B, E, H, and
inimal injury is present with microspheres; and extensive injury is present with cho-: J to L
eries; me (K) and cholesterol crystals embedded in the surface (L).
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526of 11 (64%) (p  0.12). The surface characteristics of the
mooth microsphere versus sharp crystal geometry may have
nfluenced the surface adherence (Fig. 4).
Light microscopic examination did not reveal any obvious
orphological injury in examined sections (n  38) of
either crystal- or microsphere-treated or in control arteries.
No crystals or microspheres were detected in any of the
histological sections by light microscopy.
Surface roughness. Fifteen perfused arterial segments for
holesterol crystals (n  5), microspheres (n  5), and
ontrol subjects (n 5) were evaluated at 5 distinct areas for
ach set of perfused arteries, yielding a sample set of 25
Table 2. Detection of Cholesterol Crystals and Microspheres by
SEM and Confocal Microscopy
Imaging Method Cholesterol Crystals Microspheres p Value
SEM 15/15 (100%) 0/13 (0%) 0.0002
CM 10/11 (90%) 7/11 (64%) NS
CM confocal microscopy; SEM scanning electron microscopy.
Figure 4. SEM and Fluorescence Images of Crystals and Microspheres
Images of cholesterol crystals without (A) and with (B) BODIPY ﬂuorescence st
BODIPY ﬂuorescence staining (confocal microscopy). SEM  scanning electron microoughness measurements for each intervention. Atomic
orce microscopy demonstrated a significant increase in
urface roughness over the intimal surface in the cholesterol
rystal–treated compared with the microsphere-treated and
BS-perfused arteries (p  0.01) (Figs. 5 and 6). Increased
surface roughness was diffuse over the entire arterial surface
exposed to cholesterol crystals whereas intimal tears by
SEM were visible only in focal areas.
Discussion
This study demonstrated that circulating cholesterol crystals
could injure the endothelial lining of the arterial wall,
diminishing normal vasoreactivity. It has already been dem-
onstrated that debris released during rupture contain great
amounts of cholesterol crystals (6–8,14). These are often
intermixed with other debris (e.g., platelets, fibrin) occlud-
ing the distal arterial bed causing impaired flow and reduced
myocardial perfusion. Thus, released cholesterol crystals do
flow downstream from the site of plaque rupture. Moreover,
(confocal microscopy). Images of microspheres without (C) and with (D)aining
scopy.
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527cholesterol crystals have been isolated from both atherec-
tomy specimens and aspirates obstructing coronary arteries
during acute coronary syndromes, confirming their pres-
ence during the acute event (8,15). Furthermore, we had
previously demonstrated that cholesterol crystallizes un-
der certain physical conditions (i.e., increase cholesterol
saturation and drop in temperature) that may trigger
plaque rupture (24). However, regardless of mechanism,
the release of cholesterol crystals into the circulation
could be clinically relevant with respect to worsening
myocardial ischemia due to endothelial injury. In our in
vitro model, endothelial injury with cholesterol crystals
was observed using various microscopic techniques, and
this was associated with physiological dysfunction of
decreased vasoreactivity to ACh but not to SN, indicating
endothelial injury.
This study also distinguished the effects of cholesterol
crystals from the less traumatic-shaped microspheres, em-
Figure 5. Roughness Scoring After Various Treatments
Box diagram demonstrating roughness score of arterial surface with atomic
force microscopy of control, crystal-treated, and microsphere-treated arter-
ies. Only the cholesterol crystal–treated artery had a signiﬁcantly increased
roughness score.
Figure 6. AFM Images
Images obtained by atomic force microscopy (AFM) demonstrated increasing s
microsphere- (B) and crystal-treated arteries (C).phasizing the importance of the geometry and sharpness of
the crystals. Although by SEM, there was evidence of some
mild endothelial injury with microspheres, that was not
enough to cause a significant change in the physiological
behavior of the endothelium. Also, fewer microspheres were
detected by microscopy compared with crystals, suggesting
that the microspheres rolled away with the flow in the
perfusion chamber whereas crystals tended to stick to the
wall because of their geometric shape. The advantage of
using the rabbit carotid artery is that it is similar in diameter
to medium-size human coronary arteries (2 mm).
The no-reflow phenomenon has been described as the
bsence of distal coronary blood flow after coronary inter-
entions (12,13). There has been much controversy regard-
ing the exact mechanism of no-reflow in the coronary
arteries after interventional procedures. However, given our
observations, it would be reasonable to infer that 2 mecha-
nisms contribute to the no-reflow, one is vasospasm from
endothelial injury and the other is obstruction by the
particulate materials including cholesterol crystals (15,16).
Moreover, recent studies have demonstrated that cholesterol
crystals also trigger an inflammatory response not dissimilar
to that described with uric acid crystals (25–27). This could
contribute to muscle inflammation and injury (28). Also, it
as been demonstrated that endothelium-dependant coro-
ary vasomotor function, tested through ACh-induced
asoreactivity, independently predicts long-term cardiovas-
ular risk after acute cardiovascular events (29). Other
xamples of end organ damage due to cholesterol crystals
nclude showering from carotid plaques causing amaurosis
ugax (30), renal damage after invasive vascular procedures
6,31), and livedo reticularis or gangrene in peripheral
rteries (32).
No-reflow has been associated with a worse clinical prognosis
33). Although treatment with intracoronary adenosine and
alcium-channel blockers helps to re-establish arterial flow, they
o not seem to have much effect on improving the size of
irregularity starting with control arteries (A) compared withurface
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528infarction (34). Our study suggests that using other agents
hat dissolve cholesterol crystals may have an important
mpact on no-reflow. It has already been demonstrated that
lcohol, statins, aspirin, and high-density lipoproteins have
n effect on dissolving cholesterol crystals (14,35–37). Fu-
ure studies may need to consider this novel aspect in the
reatment of no-reflow.
In addition to help explaining the no-reflow phenome-
on, our study may partially explain anginal and ischemic
pisodes that have been shown to occur in the absence of
bstructive coronary artery disease (10), as well as recurrent
vents after an acute coronary syndrome (11). Even during
n acute cardiovascular event that does not completely
cclude the circulation, cholesterol crystals may still cause
ndothelial damage that can induce ischemia. In these cases,
he coronary vasculature may seem to be relatively intact
hen subsequently evaluated with angiography or intravas-
ular ultrasound.
Study limitations. A limitation of this study was that it was
performed in vitro where the crystals were recirculated, thus
amplifying intimal injury as compared to what would be
expected in vivo where 1 pass would occur during an
acute event or after an interventional procedure. How-
ever, the process of crystal release in vivo may also be
recurring for a certain period from a ruptured plaque after
the initial event. Additional studies will need to evaluate
these aspects.
Conclusions
In summary, we have demonstrated that cholesterol crystals
in the arterial circulation as released during plaque rupture
can cause endothelial cell injury resulting in decreased
vasoreactivity. The preserved vasodilation in response to SN
suggests that this effect was due to endothelial injury. In
addition to vascular dysfunction after acute coronary syn-
drome and no-reflow after interventions, these findings may
help elucidate the mechanisms underlying previously un-
clear clinical syndromes including vasospastic angina.
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